Revenue drops 27% as Integrated BioPharma (OTCQX: INBP) swings to loss
Rhea-AI Filing Summary
Integrated BioPharma, Inc. reported weaker results for the quarter ended March 31, 2026, with revenue of $10.1 million versus $13.9 million a year earlier, a 27.3% decline. The company swung from operating income of about $0.7 million to an operating loss of about $1.1 million, and from net income of about $0.6 million to a net loss of about $0.8 million, or $(0.03) per diluted share.
For the nine months ended March 31, 2026, revenue was $34.1 million compared to $40.2 million, down 15.2%, with a net loss of about $1.5 million versus net income of about $1.0 million a year earlier. Management noted that revenue from the two largest customers in the Contract Manufacturing Segment represented about 90% of total revenue in the 2026 period, up from 83% in 2025, underscoring significant customer concentration.
Positive
- None.
Negative
- Revenue and earnings deterioration: Quarterly revenue fell 27.3% to $10.1 million, and the company moved from net income of about $0.6 million to a net loss of about $0.8 million. For the nine-month period, revenue declined 15.2% and net income turned into a loss of about $1.5 million.
- Heightened customer concentration risk: Revenue from the two largest customers in the Contract Manufacturing Segment increased to about 90% of total revenue in the nine months ended March 31, 2026, up from 83% a year earlier, increasing dependence on a small number of customers.
Insights
Integrated BioPharma showed double-digit revenue declines and moved from profit to loss.
Integrated BioPharma reported quarterly revenue of $10.1 million, down 27.3% year over year, and a net loss of about $0.8 million versus prior net income of about $0.6 million. For the nine-month period, revenue fell 15.2% to $34.1 million, with results deteriorating from net income of about $1.0 million to a net loss of about $1.5 million.
Profitability weakened as the company shifted from operating income to operating losses for both the quarter and nine-month period. Additionally, revenue concentration increased: the two largest customers in the Contract Manufacturing Segment represented about 90% of total revenue in the 2026 nine-month period, up from 83% in 2025. This heightens exposure to any changes in orders from those customers.
Overall, the combination of declining sales, negative earnings, and greater customer concentration is unfavorable compared with the prior year. Future company disclosures will clarify whether management can stabilize revenue and restore profitability while managing the risks tied to its largest customers.
8-K Event Classification
Key Figures
Key Terms
Condensed Consolidated Statements of Operations financial
Contract Manufacturing Segment financial
forward-looking statements regulatory
Risk Factors regulatory
Earnings Snapshot
|
|
|
|
(COMMISSION FILE NUMBER)
|
(I.R.S. EMPLOYER IDENTIFICATION NO.)
|
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
None
|
None
|
None
|
|
99.1
|
Press Release dated May 8, 2026
|
|
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
|
Exhibit
|
|
Description
|
|
99.1
|
|
Press Release dated May 8, 2026
|
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |
|
INTEGRATED BIOPHARMA, INC.
|
|
|
Date: May 8, 2026
|
By: /s/ Dina L Masi
|
|
Dina L. Masi
|
|
|
Chief Financial Officer
|
NEWS RELEASE for May 8, 2026
Contact: Dina Masi, CFO
Integrated BioPharma, Inc.
investors@ibiopharma.com
888.319.6962
Integrated BioPharma Reports Results for its Quarter Ended March 31, 2026
HILLSIDE, NEW JERSEY (May 8, 2026) - Integrated BioPharma, Inc. ((OTCQX: INBP)) (the “Company” or “INBP”) reports its financial results for the quarter ended March 31, 2026.
Revenue for the quarter ended March 31, 2026 was $10.1 million compared to $13.9 million for the quarter ended March 31, 2025, a decrease of $3.8 million or 27.3%. The Company had an operating loss of $1.1 million in the quarter ended March 31, 2026 compared to operating income in the quarter ended March 31, 2025 of approximately $0.7 million.
Revenue for the nine-month period ended March 31, 2026 was $34.1 million compared to $40.2 million for the nine-month period ended March 31, 2025, a decrease of $6.1 million or 15.2%. The Company had an operating loss for the nine-month period ended March 31, 2026 of approximately $1.8 million and operating income of approximately $1.4 million for the nine-month period ended March 31, 2025.
For the quarters ended March 31, 2026 and 2025, the Company had a net loss of $0.8 million and net income of approximately $0.6 million, respectively. The Company’s net (loss) income per share of common stock and diluted net (loss) income per share of common stock for the quarters ended March 31, 2026 and 2025 were $(0.03) and $0.02 per share of common stock, respectively.
For the nine-month periods ended March 31, 2026 and 2025, the Company had a net loss of $1.5 million and net income of approximately $1.0 million, respectively. The Company’s net (loss) income per share of common stock and diluted net (loss) income per share of common stock for the nine months ended March 31, 2026 and 2025 were $(0.05) and $0.03 per share of common stock, respectively.
“Our revenue decreased by approximately 15% in the nine-month period ended March 31, 2026 from the nine-month period ended March 31, 2025 and our revenue from our two largest customers in our Contract Manufacturing Segment represented approximately 90% and 83% of total revenue in the nine months ended March 31, 2026 and 2025, respectively,” stated the Co-Chief Executive Officers of the Company, Riva Sheppard and Christina Kay.
A summary of our financial results for the three and nine months ended March 31, 2026 and 2025 follows:
|
INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES |
||||||||||||||||||
|
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS |
||||||||||||||||||
|
(In thousands, except share and per share amounts) |
||||||||||||||||||
|
(Unaudited) |
||||||||||||||||||
|
Three Months Ended |
Nine Months Ended |
|||||||||||||||||
|
March 31, |
March 31, |
|||||||||||||||||
|
2026 |
2025 |
2026 |
2025 |
|||||||||||||||
|
Total revenue |
$ | 10,107 | $ | 13,947 | $ | 34,076 | $ | 40,178 | ||||||||||
|
Cost of sales |
10,383 | 12,396 | 33,304 | 36,085 | ||||||||||||||
|
Gross (loss) profit |
(276 | ) | 1,551 | 772 | 4,093 | |||||||||||||
|
Selling and administrative expenses |
809 | 812 | 2,608 | 2,662 | ||||||||||||||
|
Operating (loss) income |
(1,085 | ) | 739 | (1,836 | ) | 1,431 | ||||||||||||
|
Other income , net |
50 | 39 | 123 | 36 | ||||||||||||||
|
(Loss) income before income taxes |
(1,035 | ) | 778 | (1,713 | ) | 1,467 | ||||||||||||
|
Income tax (benefit) expense, net |
(198 | ) | 167 | (237 | ) | 481 | ||||||||||||
|
Net (loss) income |
$ | (837 | ) | $ | 611 | $ | (1,476 | ) | $ | 986 | ||||||||
| Net (loss) income per common share: | ||||||||||||||||||
|
Basic |
$ | (0.03 | ) | $ | 0.02 | $ | (0.05 | ) | $ | 0.03 | ||||||||
| Diluted | $ | (0.03 | ) | $ | 0.02 | $ | (0.05 | ) | $ | 0.03 | ||||||||
|
|
||||||||||||||||||
| Weighted average common shares outstanding: | ||||||||||||||||||
| Basic | 31,059,610 | 30,300,720 | 31,059,610 | 30,190,869 | ||||||||||||||
|
Diluted |
31,059,610 | 31,514,591 | 31,059,610 | 30,960,916 | ||||||||||||||
About Integrated BioPharma Inc. (INBP)
Integrated BioPharma, Inc. (“INBP”) is engaged primarily in the business of manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. Further information is available at ir.ibiopharma.com.
This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, as well as assumptions, that, if they never materialize or prove incorrect, could cause the results of INBP to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements generally are identified by the words “expects,” “anticipates,” believes,” intends,” “estimates,” “should,” “would,” “strategy,” “plan” and similar expressions. All statements other than statements of historical fact are statements that could be deemed forward-looking statements and are not guarantees of future performance. Such statements speak only as of the date hereof, are subject to change and should not be relied upon for investment purposes. INBP undertakes no obligation to revise or update any statements for any reasons. The risks, uncertainties and assumptions include, among others, changes in general economic and business conditions; loss of market share through competition; introduction of competing products by other companies; the timing of regulatory approval and the introduction of new products by INBP; changes in industry capacity; pressure on prices from competition or from purchasers of INBP’s products; regulatory changes in the pharmaceutical manufacturing industry and nutraceutical industry; regulatory obstacles to the introduction of new technologies or products that are important to INBP; availability of qualified personnel; the loss of any significant customers or suppliers; inflation, including inflationary pressures from any tariffs, and tightened labor markets; our ability to expand our customer base and other risks and uncertainties described in the section entitled “Risk Factors” in INBP’s most recent Annual Report on Form 10-K and its subsequent Quarterly Reports on Form 10-Q. Accordingly, INBP cannot give assurance that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on the results of operations or financial condition of INBP.